肾细胞癌患者接受纳武利尤单抗与卡博替尼免疫治疗后,18F-FDG PET/CT检出甲状腺功能障碍
本文阐述靶向免疫治疗为癌症治疗的前沿方法,PD-1抑制剂纳武利尤单抗与酪氨酸激酶抑制剂卡博替尼通过增强正常组织免疫反应可导致免疫相关不良事件,甲状腺功能障碍是常见类型,可在治疗后18F-FDG PET/CT扫描中观察到。
要点
- 纳武利尤单抗阻断PD-1促进抗肿瘤免疫,卡博替尼抑制VEGFR 1、2、3酪氨酸激酶活性。
- 免疫治疗增强正常组织免疫反应可致免疫相关不良事件。
- 甲状腺功能障碍是常见免疫相关不良事件,可在治疗后18F-FDG PET/CT中检出。
核心结论
- 靶向免疫治疗增强正常组织免疫反应可导致免疫相关不良事件,甲状腺功能障碍是常见类型,可在治疗后18F-FDG PET/CT扫描中观察到。
主要发现
- 纳武利尤单抗为全人源免疫球蛋白G4,阻断PD-1并促进抗肿瘤免疫。
- 卡博替尼抑制血管内皮生长因子受体1、2、3的酪氨酸激酶活性。
- 甲状腺功能障碍是常见免疫相关不良事件,见于治疗后18F-FDG PET/CT扫描。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Targeted immunotherapy became the most advanced approach for cancer treatment. Programmed death-1 (PD-1) expressed on activated T cells can reverse immune suppression and cause T-cell activation. Nivolumab, a PD-1 immune checkpoint inhibitor antibody that is a fully human immunoglobulin G4, blocks PD-1 and promotes antitumor immunity. Cabozantinib (tyrosine kinase inhibitor) inhibits the tyrosine kinase activity of vascular endothelial growth factor receptors 1, 2, and 3. As a result of enhancing immune response in normal tissues, immune-related adverse events can occur. Thyroid dysfunction is a common form of immune-related adverse event and seen on 18 F-FDG PET/CT scans post therapy.
引用
- Reddy M, Ravina M, Goyal H, et al. Nivolumab and Cabozantinib Immunotherapy Induced Thyroid Dysfunction Detected on 18 F-FDG PET/CT in Renal Cell Carcinoma. Clin Nucl Med. 2024. PMID: 39192514. doi:10.1097/RLU.0000000000005407
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。